Breaking the 1% unbound threshold: an IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds
Drug Metabolism and Disposition · 2026
DOI: 10.1016/j.dmd.2026.100358 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026. Verfasst von Faraz Kazmi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Preclinical Sciences & Translational Safety, Johnson & Johnson, Spring House, Pennsylvania. Electronic address: fkazmi@its.jnj.com. Hauptthemen laut MEDLINE: Blood Proteins. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
The reliable measurement of plasma protein binding (PPB) is crucial for understanding drug pharmacokinetics and predicting drug-drug interactions (DDIs). Historically, regulatory guidelines had imposed a cutoff of 1% for the unbound fraction (fu) of highly bound drugs, leading to concerns about overestimating DDI risks and triggering unnecessary clinical DDI trials. In this study, an IQ working group comprising 11 member companies evaluated the interlab accuracy and precision of the PPB determination of 20 compounds highly bound to plasma proteins with fu values
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Preclinical Sciences & Translational Safety, Johnson & Johnson, Spring House, Pennsylvania. Electronic address: fkazmi@its.jnj.com.
- NCE Drug Metabolism & Pharmacokinetics, The Healthcare Business of Merck KGaA, Darmstadt, Germany.
- Clinical Pharmacology Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Boston, Massachusetts.
- In vitro ADME, Preclinical Development, Bayer AG, Wuppertal, Germany.
- DMPK, GSK, Collegeville, Pennsylvania.
- DMPK, GSK, Stevenage, Hertfordshire, UK.
Zitieren
APA
Kazmi, F., Gradhand, U., Gangl, E. T., Fricke, R., Aldinger, T., Chambers, R., Donzelli, M., Ferguson, D., Francq, B. G., Harradine, P. J., Kazma, R., Mardirosian, S., Nicolas, J. M., Shinkyo, R., Simon, S., Sinz, M., Stuart, P., Tatikola, K., Wittwer, M. B., …, & Kalvass, J. C. (2026). Breaking the 1% unbound threshold: an IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2026.100358
Vancouver
Kazmi F, Gradhand U, Gangl ET, Fricke R, Aldinger T, Chambers R, et al. Breaking the 1% unbound threshold: an IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds. Drug Metabolism and Disposition. 2026. doi:10.1016/j.dmd.2026.100358
BibTeX
@article{Kazmi2026,
author = {Kazmi, Faraz and Gradhand, Ulrike and Gangl, Eric T and Fricke, Robert and Aldinger, Tanya and Chambers, Rob and Donzelli, Massimiliano and Ferguson, Douglas and Francq, Bernard G and Harradine, Paul J and Kazma, Rémi and Mardirosian, Saro and Nicolas, Jean-Marie and Shinkyo, Raku and Simon, Sandrine and Sinz, Michael and Stuart, Patricia and Tatikola, Kanaka and Wittwer, Matthias Beat and Vendrell-Navarro, Gloria and Yan, Zhengyin and Kalvass, John C},
title = {Breaking the 1% unbound threshold: an IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds},
journal = {Drug Metabolism and Disposition},
year = {2026},
doi = {10.1016/j.dmd.2026.100358}
}
EUVIMED